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Abstract
Regeneration after hematopoietic stem cell transplantation (HSCT) depends on enormous activation of the stem cell pool.
So far, it is hardly understood how these cells are recruited into proliferation and self-renewal. In this study, we have
addressed the question if systemically released factors are involved in activation of hematopoietic stem and progenitor cells
(HPC) after autologous HSCT. Serum was taken from patients before chemotherapy, during neutropenia and after
hematopoietic recovery. Subsequently, it was used as supplement for in vitro culture of CD34
+ cord blood HPC. Serum taken




2) for more cell divisions and increased colony forming units (CFU) as well as
the number of cobblestone area-forming cells (CAFC). The stimulatory effect decays to normal levels after hematopoietic
recovery (more than 2 weeks after HSCT). Chemokine profiling revealed a decline of several growth-factors during
neutropenia, including platelet-derived growth factors PDGF-AA, PDGF-AB and PDGF-BB, whereas expression of monocyte
chemotactic protein-1 (MCP-1) increased. These results demonstrate that systemically released factors play an important
role for stimulation of hematopoietic regeneration after autologous HSCT. This feedback mechanism opens new
perspectives for in vivo stimulation of the stem cell pool.
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Introduction
Hematopoietic stem cell transplantation (HSCT) has evolved
from a highly experimental procedure to a standard therapy for
several malignant and hereditary diseases [1]. Pioneering work was
done more than 50 years ago by Thomas and colleagues [2]. Since
then, allogeneic and autologous transplantation settings are
commonly used for reconstitution of blood formation after high-
dose chemotherapy. Hematopoietic recovery is usually observed
within weeks. Despite this clinical success, it is yet unclear what
governs this enormous regenerative potential and activation of
hematopoietic stem cells (HSC) in their niche [3].
Over the last decades, umbilical cord blood (CB) has become a
viable option for HSC transplants [4]. Especially for CB, the
amount of transplantable HSC is limited by the available volume –
therefore in vitro expansion might provide new perspectives for
HSCT. Several growth factors have been shown to be relevant for
stimulation of proliferation and maintenance of primitive function
under in vitro conditions [5–8]. Cellular support such as
mesenchymal stromal cells (MSC) can further enhance expansion
of hematopoietic progenitor cells (HPC) [9–11]. Recently, the aryl
hydrocarbon receptor antagonist StemRegenin 1 (SR1) has been
shown to promote in vitro expansion of HSC [12]. Several of these
approaches are currently addressed in clinical trials, but at the
moment no proof exists that these expansion techniques improve
performance after HSCT.
The most essential mechanism for hematopoietic recovery after
transplantation is activation of the stem cell pool. These cells are
defined by the dual ability to self-renew and to differentiate into
distinct cell types, whereas they reside in a quiescent state under
steady state conditions [13,14]. Mathematical modeling indicated
that it is more effective to increase the self-renewal rate than the
proliferation rate in the course of autologous HSC transplantation
and this should be mediated by a feedback mechanism [15]. A
better understanding of these mechanisms might facilitate more
reliable and faster hematopoietic recovery without the need of
higher HSC numbers.
So far, research has mainly focused on characterization of HSC
and methods for their in vitro expansion [16]. In contrast, methods
for activation of stem cell function in the course of HSCT have
hardly been addressed. The highest activation of self-renewal
might be anticipated during neutropenia following high-dose
chemotherapy. Under these conditions, the hematopoietic system
is under an enormous regenerative pressure, and this might be
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e18012regulated by systemically released feedback signals. Therefore, we
have taken serum samples from patients in the course of
autologous HSCT to evaluate their effect on proliferation and
maintenance of primitive function of hematopoietic progenitor
cells.
Results
Proliferation of HPC is stimulated by serum after HSCT
Fifty-one serum samples were harvested from nine patients
before and after HSCT (table 1). Culture medium was
supplemented with 10% of these serum samples for subsequent
in vitro expansion of CD34
+ cells from umbilical cord blood.
Proliferation of HPC was analyzed after one week by MTT assay
(figure 1). Serum samples which were taken 8 days after HSCT (d8
serum; during neutropenia) significantly enhanced proliferation of
HPC in comparison to those taken before chemotherapy (BC
serum; experiments were repeated with serum samples of 7
patients, p=0.03). This growth-promoting effect was also
observed in co-culture with mesenchymal stromal cells (MSC;
p=0.0017). Direct counting of cell numbers revealed a 1.97-fold
higher proliferation of HPC with d8 serum as compared to BC
serum under culture conditions without MSC (experiments were
repeated with serum samples of four patients, p=0.0081). Overall,
the results clearly demonstrate that serum taken during hemato-
poietic stress after HSCT significantly enhances proliferation of
HPC in vitro.
Maintenance of CD34 expression in HPC is enhanced by
serum after HSCT
For simultaneous analysis of cell divisions and immunopheno-
type, we have stained freshly isolated CD34
+ cells from cord blood
with carboxyfluorescein diacetate N-succinimidyl ester (CFSE).
After seven days, residual CFSE dye was analyzed together with
immunophenotypic markers (figure 2). Proliferation of HPC was
always markedly increased with serum supplements taken 4 or 8
days after HSCT in comparison to serum isolated before
chemotherapy. In contrast, no increase in proliferation was
observed with serum taken 18 days or 22 days after HSCT. Co-
culture with MSC greatly enhanced survival and proliferation of
HPC in vitro and facilitated up to 12 cell divisions. Proliferation
under these co-culture conditions was further increased by
addition of serum samples which were taken 4 and 8 days after
HSCT.
Notably, expression of primitive surface markers was also
maintained for more cell divisions by addition of serum taken
under hematopoietic stress: CD34 expression level was higher, and
it was maintained for more than five cell divisions by supplemen-
tation of serum derived from 4 days or 8 days after HSCT.
Furthermore, up-regulation and decay of CD38 expression were
shifted to higher numbers of cell division. These effects were
consistent in all experiments and with all patient samples used in
this study. Taken together, addition of serum which was taken
during neutropenia significantly enhances proliferation of HPC
and maintains expression of CD34 for more cell divisions.
Serum after HSCT enhances expansion of colony forming
units
Subsequently, we determined colony forming unit (CFU)
potential to estimate expansion of HPC. CD34
+ cells were
cultured for seven days with serum taken either before
chemotherapy or eight days after HSCT (d8). Day 8 serum
significantly increased CFU frequency of granulocyte (CFU-G;
p=0.001), macrophage (CFU-M; p=0.046) and erythrocyte
lineage (CFU-E; p=0.009; figure 3). There was no bias for
specific lineage specification. The number of colonies was about
tenfold higher after culture-expansion with MSC, and even under
co-culture conditions, expansion of CFU was significantly
increased by addition of d8 serum (p=0.039).
Alternatively, we have analyzed the frequency of cobblestone
area-forming cells (CAFC) at day 28 to estimate the fraction of
more primitive progenitor cells. In culture medium supplemented
with d8 serum, the CAFC frequency was about 16-fold higher as
compared to culture conditions with serum BC (p=0.0358). These
data provide further evidence that serum samples of neutropenic
patients contain factors which enhance expansion of HPC in vitro.
Up-regulation of lineage-markers
Culture conditions might stimulate differentiation of HPC
towards specific lineages. As described above, CD34
+ cells hardly
proliferated if cultured with 10% BC serum, and they hardly
express specific lineage markers (figure 4, figure S1). Expansion
with d8 serum showed a moderate up-regulation of CD3 and
Table 1. Serum samples for culture expansion of HPC.









# 1 21 f NHL BEAM* 1 to 8 2 to 12 BC, 21, 4, 8, 14, 22
# 2 60 m NHL BEAM* 1 to 7 3 to 10 BC, 21, 4, 8,14
# 3 58 f MM Melphalan* 5 to 9 8 to 11 BC, 1, 4, 8, 11, 14, 18
# 4 65 m MM Melphalan* 5 to 10 6 to 11 BC, 1, 4, 8, 11
# 5 55 m MM Melphalan* 5 to 10 6 to 14 BC, 1, 4, 8, 11
# 6 32 m NHL BEAM* 2 to 9 4 to 9 BC, 1, 4, 6, 8, 11
# 7 64 f MM Melphalan* 5 to 9 7 to 9 BC, 1, 4, 8, 11
# 8 61 f MM Melphalan 6 to 15 7 to 13 BC, 1, 4, 8, 11, 14, 18
# 9 61 m MM Melphalan 6 to 13 9 to 18 BC, 4, 8, 11, 14
MM= multiple myeloma; NHL = non-Hodgkin lymphoma; melphalan =200 mg/m
2 on d-2; BEAM = carmustine 300 mg/m
2 d-7, etoposide 150 mg/m
2 d-7 to -4,
cytosine arabinoside 200 mg/m
2 d-7 to -4 and melphalan 140 mg/m
2 d-3;
*= G-CSF stimulation from d0 until end of neutropenia; BC = before chemotherapy.
doi:10.1371/journal.pone.0018012.t001
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indicate a starting differentiation towards lymphoid lineage.
Notably, up-regulation of these lymphatic markers seems to be
suppressed in co-culture with MSC, whereas co-culture with MSC
resulted in a moderate increase of the myeloid markers CD13 and
CD33 after eight cell divisions. This is in line with other studies
indicating that differentiation of cells cultured on human MSC
primarily shifts toward myeloid lineage [17,18]. The common
leukocyte antigen CD45 was always up-regulated after about eight
cell divisions, whereas no positive staining was observed for the
NK cell marker CD56. Expression of CD133 decayed after several
cell divisions in accordance to CD34. Notably, expression of this
marker for primitive HPC (prominin 1) was also maintained for
more cell divisions if cultured with d8 serum. These results support
the notion that serum of neutropenic patients enhances prolifer-
ation of HPC and maintains their primitive phenotype for more
cell divisions.
Chemokine profiling of serum samples
To determine which growth factors contribute to enhanced
hematopoietic regeneration after autologous HSCT, we used
Human Cytokine Antibody Arrays for analysis of 174 chemokines
(figure S2). Chemokine profiles of six patients were compared in
serum samples before chemotherapy and day 8 after HSCT
(figure 5). Unexpectedly, pair wise comparisons revealed signifi-
cant down-regulation of eight proteins in d8 serum: platelet-
derived growth factor (PDGF)-AA (p=0.009), PDGF-AB
(p=0.048), PDGF-BB (p=0.023), matrix metallopeptidase-9
(MMP-9; p=0.036), leukocyte alkaline phosphatase (LAP;
p=0.048), L-Selectin (p=0.036), leukemia inhibitory factor
(LIF; p=0.009) and chemokine [C-X-C motif] ligand 10
(CXCL10 or IP-10; p=0.006). The only moderate increase was
observed for monocyte chemotactic protein-1 (MCP-1; p=0.048).
Furthermore, we analyzed one patient’s serum samples at
additional time points (patient 3: BC, d4, d8, d11, d14 and d18
after HSCT). This kinetic revealed that expression of these
chemokines decayed during neutropenia and returned to pre-
chemotherapy level 18 days after HSCT (figure 5).
Down-regulation of PDGF in day 8 serum samples might be
associated with lower platelet counts and this could also contribute
to the feedback signal which activates hematopoiesis. We have
addressed the effect of PDGF in our culture system using serum-
free conditions supplemented with 20 ng/mL TPO, 10 ng/mL
FGF, 10 ng/mL SCF together with different concentrations of
PDGF (0, 1, 10 and 100 ng/mL; figure S3). PDGF did not have
any effect on proliferation of HPC without stromal support. In co-
culture with MSC, addition of 100 ng/mL PDGF slightly
impaired proliferation of HPC. Correspondingly, the relative
CFSE intensity increased from 12.39 to 21.44 (p=0.03; n=7;
figure S3). However, PDGF did not affect CD34 expression, and
there was no consistent effect on colony formation either without
or with co-culture. Alternatively, we analyzed if up-regulation of
MCP-1 was responsible for the stimulatory effect on HPC. CD34
+
cells were cultured in medium either with 10% patient serum BC
or with TPO, FGF and SCF as mentioned above. These media
were supplemented with different concentrations of MCP-1 (0, 1,
10 and 100 ng/ml). Overall, MCP-1 did not have significant
impact on proliferation or CD34 expression (figure S4).
Discussion
The present study provides evidence that systemically released
factors mediate the enormous regeneration after chemotherapy-
induced myelosuppression. Under steady state conditions, HSC
reside in a dormant state within their stem cell niche. In contrast,
hematopoietic stress recruits HSC into proliferation [13]. In
HSCT, the progeny of about 2610
8 CD34
+ cells gives rise to more
than 3610
10 leucocytes in the peripheral blood. Hence, there has
to be a more than hundred-fold increase in cell numbers within
two to three weeks [15]. It has been shown that higher numbers of
CD34
+ cells in the transplant enhance hematopoietic recovery
[19–21]. On the other hand, stimulation of stem cell function after
transplantation appears to be at least equally important.
Expansion of HSC requires both: proliferation to increase cell
numbers and maintenance of their primitive phenotype and
function. This has often been considered as oxymoron: prolifer-
ation under in vitro conditions usually results in loss of ‘‘stemness’’.
Figure 1. Serum after HSCT stimulates proliferation of CD34
+ cells. Serum samples were taken before chemotherapy and eight days after
autologous HSCT, when leukocyte counts are at a minimum. Serum was subsequently supplemented for in vitro expansion of CD34
+ cells for 1 week
either without stromal support or with co-culture of mesenchymal stromal cells (MSC). Analysis was either performed with the MTT-assay (A) or using
a cell counter to determine fold-expansion rates (B). Serum from neutropenic patients significantly increased proliferation of HPC (* p,0.05;
** p,0.01; error bars represent SD).
doi:10.1371/journal.pone.0018012.g001
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several cell divisions by using the CFSE-dilution method [7,22,23].
Notably, loss of CD34 expression and the peak of CD38
expression shifted to higher numbers of cell divisions with serum
at day 8 after HSCT. Furthermore, these serum samples
significantly enhanced CFU frequency and CAFC frequency. It
has to be noted that seven out of nine patients received G-CSF to
accelerate hematopoietic recovery after HSCT and this chemo-
kine might affect these results. However, the very same effect was
also observed in the other two patients without G-CSF as well as
with serum samples which were taken after chemotherapy but
before the first G-CSF application. Furthermore, G-CSF serum
levels seemed to be very low at the time of blood sampling as it was
not detected by cytokine profiling. Therefore, the stimulatory
effect of serum after autologous transplantation has to be
attributed to other activating molecules.
The stem cell niche in the bone marrow is composed of multiple
different cell types and hematopoiesis is probably regulated by an
orchestra of different growth factors, extracellular matrix proteins,
oxygen pressure and adhesion proteins [14,24]. Co-culture
experiments with MSC demonstrated that cell-cell contact with
stromal cells greatly enhances proliferation and maintenance of
primitive markers. Various adhesion proteins have been shown to
be involved in this process [9,11,25–27]. This is complemented by
a multitude of studies that demonstrated the importance of growth
factors for in vitro culture of HSC – especially of cytokine mixtures
Figure 2. Proliferation and immunophenotype of HPC upon expansion with serum samples. CD34
+ hematopoietic progenitor cells (HPC)
were stained with CFSE and subsequently cultivated for seven days in vitro either without stromal support (A) or with MSC (B). Culture medium was
supplemented with serum samples taken before chemotherapy (BC) or at different time points after HSCT (d4, d8, d11, d14 and d18). Flow cytometric
analysis was used to monitor cell division history by residual CFSE staining (red line indicates five cell divisions). CD34 and CD38 expression was
analyzed in relation to the number of cell divisions. Representative histograms for analysis of all nine patients are demonstrated.
doi:10.1371/journal.pone.0018012.g002
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co-workers [30] demonstrated that systemic administration of
pleiotrophin (PTN) causes a substantial increase in the regener-
ation of HSC in vivo after total body irradiation of mice. Thus,
better insight into the underlying mechanisms of hematopoietic
regeneration might increase recovery rates.
So far, only few studies have analyzed secretion of growth
factors after chemotherapy. It has been shown that TPO levels
increase one week after intensive chemotherapy and decline after
three weeks, indicating that TPO plays a critical role for
reconstitution of megakaryopoiesis and platelet production
following HSCT [31,32]. Other authors demonstrated that
interleukin-6 (IL-6) levels rise in patients with chemotherapy-
induced myelosuppression [32,33]. We did not observe significant
up-regulation of TPO, and there was only a moderate increase of
IL-6 after HSCT (p=0.09). Unexpectedly, the most significant
changes upon chemotherapy induced myelosuppression were
down-regulation of several growth factors. Chemokines work in
concert, and it is also conceivable that some of them exert negative
effects on hematopoiesis – their down-regulation might corre-
spondingly stimulate self-renewal of HSC [34,35]. For example, it
has been shown that IP-10 suppresses colony formation of HPC in
a dose dependent manner [36]. This is in line with our observation
that IP-10 levels decrease 8 days after HSCT. The significant
decrease observed for the three isoforms of PDGF might result
from lower platelet counts after chemotherapy. Other authors
have indicated that PDGF is involved in expansion of HPC, but its
role is not yet fully understood [37]. Recently, Aghideh et al [38]
provided evidence that platelet derived growth factors suppress the
expansion of CD133
+ HPC. We observed an inhibitory effect of
PDGF on proliferation of HPC only in co-culture with MSC. This
effect might also result indirectly from activating MSC. Overall, it
is yet unclear if the hematopoiesis supportive effect can be
attributed to chemokines or rather to other molecules [39].
Figure 3. Colony forming unit frequency is enhanced by serum of aplastic patients. CD34
+ HPC were cultured either without stroma (A) or
in co-culture with MSC (B) in culture medium supplemented with serum taken before chemotherapy or day 8 after HSCT. After seven days of in vitro
expansion, cells were re-seeded in methylcellulose medium and after two weeks numbers of granulocyte (CFU-G), macrophage (CFU-M) and
erythrocyte colonies (CFU-E) were counted. Overall, colony formation was enhanced upon expansion with d8 serum. CFU-frequency was greatly
increased by co-culture with MSC, and this was further stimulated by serum from d8. Furthermore, cobblestone area forming cell (CAFC) frequency
was determined after 4 weeks of co-culture with MSC (C). The CAFC frequency was greatly enhanced by addition of d8 serum (D) (n=4; * =p,0.05;
** =p,0.01; error bars represent SEM; size bar =100 mm).
doi:10.1371/journal.pone.0018012.g003
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relevant for the stimulatory effect of serum samples, and this will
be addressed in the future.
Conclusion
Reliable protocols for in vitro expansion of HSC are often
considered as Holy Grail for stem cell research [40]. However, it
might be much more effective to enhance hematopoietic recovery
by activation of the stem cell pool in vivo. Our results provide
evidence that this is at least partly mediated by systemically
released factors. Proliferation, maintenance of primitive immuno-
phenotype and CFU frequency were significantly enhanced by
addition of serum samples taken during hematopoietic stress after
HSCT. Identification of molecules that recruit HSC into action
might provide new perspectives to increase recovery after
chemotherapy.
Materials and Methods
Serum samples in the course of autologous HSCT
Ten milliliter peripheral blood were collected from patients with
multiple myeloma (MM) or non-Hodgkin lymphoma (NHL;
table 1) after written consent using guidelines specifically approved
by the Ethic Committee of RWTH Aachen University (Permit
Number: EK155/09). High dose chemotherapy preceding the
stem cell rescue for patients suffering from MM was performed
with high dose melphalan (200 mg/m
2 on day -2). NHL patients
received BEAM chemotherapy (BCNU 300 mg/m
2 d-7, etoposide
150 mg/m
2 d-7 to d-4, cytosine arabinoside 200 mg/m
2 d-7 to d-
4 and melphalan 140 mg/m
2 d-3). At day 0 all patients were
transplanted with a mean number of CD34
+ cells of 5.0610
6 per
kg body weight (ranging from 2.8 to 10.6610
6). Blood samples
were collected at different days in the course of HSCT - before
chemotherapy (BC), one day before HSCT (d-1) and at different
time points after transplantation (d1, d4, d8, d11, d14, d18 and
d22). Blood samples were transferred into a 15 mL tube (Greiner,
Kremsmu ¨nster, Austria), agitated horizontally at 37uC for 1 h to
allow coagulation, then incubated upright at 4uC for 4 h and
finally centrifuged at 8406 g for 15 min [41]. Supernatant was
aliquoted and stored at 280uC until use.
Isolation of hematopoietic progenitor cells
CD34
+ cells were isolated from fresh umbilical cord blood after
written consent using guidelines specifically approved by the Ethic
Committee of RWTH Aachen University (Permit Number:
EK187/08). Mononuclear cells (MNC) were separated by density
gradient centrifugation on Biocoll (Biochrom KG, Berlin,
Germany) and CD34
+ cells were enriched using the human
CD34 Micro Bead Kit on a MiniMACS system according to the
manufacturer’s instructions (Miltenyi Biotec GmbH, Bergisch-
Gladbach, Germany) as described before [9].
Isolation of mesenchymal stromal cells from human bone
marrow
MSC were isolated from the caput femoris after the patient’s
written consent using guidelines specifically approved by the Ethic
Committee of RWTH Aachen University (Permit Number:
EK128/09). Bone fragments were flushed with PBS and MNC
were subsequently isolated by density gradient centrifugation on
Biocoll (Biochrom KG). MSC were seeded in 10 ng/mL
fibronectin (Sigma-Aldrich, Steinheim, Germany) coated tissue
culture flasks (Nunc, Roskilde, Denmark) and cultivated in
Dulbecco’s Modified Eagles Medium-Low Glucose (DMEM-LG,
PAA, Pasching, Austria) supplemented with 2 mM L-glutamine
(Sigma), 100 U/mL penicillin/streptomycin (pen/strep; Lonza,
Figure 5. Chemokine profiling in the course of HSCT. 174 human serum proteins were analyzed in serum samples of six patients (#1–6)
obtained before chemotherapy (BC) or at day 8 after HSCT. Detection of platelet-derived growth factor (PDGF)-AA, -AB, -BB, matrix metallopeptidase -
9 (MMP-9), leukocyte alkaline phosphatase (LAP), L-Selectin, leukemia inhibitory factor (LIF) and chemokine [C-X-C motif] ligand 10 (IP-10) was higher
before chemotherapy, whereas only chemokine [C-C motif] ligand 2 (MCP-1) significantly increased after chemotherapy. Additional comparison of
chemokine profiles in serum samples at further time points (BC and from d4, d8, d11, d14 and d18 after HSCT) revealed that these changes in growth-
factor concentration are transient during aplasia and normalize after hematopoietic recovery.
doi:10.1371/journal.pone.0018012.g005
Figure 4. Analysis of lineage markers. CD34
+ HPC were stained with CFSE and cultured either without stroma (A) or in co-culture with MSC (B) in
culture medium supplemented either with 10% BC serum or 10% d8 serum. After seven days expression of CD3, CD13, CD19, CD33, CD45, CD56 and
CD133 were analyzed by flow cytometry. Representative results for four patients are demonstrated (each of them performed in duplicate).
doi:10.1371/journal.pone.0018012.g004
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2 U/mL heparin to avoid gelatinization as described before [42].
Culture medium was changed twice per week. When reaching
80% confluence, MSC were trypsinized, counted by a Neubauer
counting chamber (Brand, Wertheim, Germany), and re-seeded at
10
4 cells per cm
2 for further expansion. For co-culture experiments
we have used MSC of passage 3 to 6 (10–15 population doublings).
Culture conditions and expansion of HPC
HPC were expanded in 24-well plates (Nunc) in StemSpan
serum free expansion medium (Stem Cell Technologies, Grenoble,
France) supplemented with 10% patient serum. Culture was either
performed without stromal support, or CD34
+ cells were seeded
on a confluent layer of MSC. In some experiments we used serum-
free medium consisting of StemSpan supplemented with 10 mg/
mL heparin (Roche GmbH, Mannheim, Germany), 20 ng/mL
trombopoietin (TPO; PeproTech GmbH, Hamburg, Germany),
10 ng/mL stem cell factor (SCF; PeproTech), 10 ng/mL fibro-
blast growth factor 1 (FGF; PeproTech) and platelet derived
growth factor (PDGF; R&D Systems, Minneapolis, MN, USA) in
concentrations as indicated in the text.
Proliferation assay
Proliferation of CD34
+ HPC under the influence of different
patient sera was assessed using the Thiazolyl Blue Tetrazolium
Bromide (MTT) assay [43]. 5,000 cells per cm
2 were expanded in
parallel with media supplemented with 10% of different serum
samples. For co-culture experiments, we have used a layer of
30,000 MSC per cm
2 after irradiation (20 Gy, IBL-437; Cis Bio
International, Bagnols, France). After seven days of cultivation,
cells were harvested by vigorous pipetting and transferred into
5 mL tubes (Becton Dickinson, San Jose, CA, USA). The samples
were centrifuged 10 min at 5006 g for pelleting of cells, the
supernatant was discarded and samples were incubated with
1 mM MTT over night at 37uC. The samples were then
centrifuged 10 min at 2,3606 g for pelleting of MTT crystals.
After discarding of supernatant, crystals were resolved in 150 ml
4 mM HCl in isopropanol, transferred into a 96-well plate, and
optical density (OD) was measured at 590 nm with a Tecan
Infinite 200 plate reader (Tecan Trading, Ma ¨nnedorf, Switzer-
land). Irradiated MSC without HPC were measured in parallel for
background normalization in co-culture experiments. Alternative-
ly, we have seeded 10,000 HPC under different culture conditions
and counted their progeny after seven days with a CASY cell
counter (Scha ¨rfe System, Reutlingen, Germany) within a diameter
range of 7 to 20 mm.
Analysis of cell division history
Freshly isolated CD34
+ cells were labeled with carboxyfluor-
escein diacetate N-succinimidyl ester (CFSE; Sigma-Aldrich) to
monitor cell divisions [9]. In brief, cells were washed in PBS and
then stained with CFSE at a final concentration of 2.5 mM in PBS
with 0.1% FCS (Fetal calf serum; PAA) for 10 min at 37uC. The
staining reaction was stopped with ice cold RPMI (PAA) with 10%
FCS for 5 min on ice followed by three washing steps with PBS.
HPC were then culture expanded and CFSE is equally distributed
to the two daughter cells with each cell division. After seven days,
CFSE intensity was measured via flow cytometry together with
additional immunophenotypic markers.
Immunophenotypic analysis
Cells were washed in PBS, stained with CD3-allophycocyanin
(APC; Becton Dickinson, San Jose, CA, USA [BD], clone HIT3a),
CD13-phycoerythrin (PE; BD, clone WM-15), CD19-APC (BD,
clone HIB19), CD45-V500 (BD, clone HI30), CD33-PE (Beckman
Coulter, Krefeld, Germany, clone D3HL60.251), CD34-APC
(BD, clone 8G12), CD38-PE (BD, clone HB-7) and CD56-PE
(BD, clone B159) in a dilution of 1:200 and analyzed using a FACS
Canto II (BD) running FACS Diva software (BD). Further analysis
was performed using WinMDI software (WinMDI 2.8; The
Scripps Institute, San Diego, CA, USA). Discrimination between
MSC and HPC was possible by forward scatter, side scatter,
propidium iodide (PI) staining and CFSE-staining.
Colony forming unit assay
Colony forming unit (CFU) potential was determined to estimate
culture expansion of HPC. 10,000 CD34
+ cells were grown for
seven days under each culture condition and their progeny was
subsequently re-seeded in different dilutions (1:1, 1:10 and 1:100
dilution) in a 24-well culture dish with 500 ml methylcellulose
mediumperwell(HSC-CFUlightwithEPO;MiltenyiBiotec).After
two further weeks, granulocyte (CFU-G), macrophage (CFU-M)
and erythrocyte colonies (CFU-E) were counted.
Cobblestone area-forming cell assay
Cobblestone area-forming cell assays (CAFC) were performed
to estimate the frequency of more primitive progenitor cells [44].
MSC were grown to confluence in flat-bottom 96-well plates and
irradiated at 20 Gy (IBL-437; Cis Bio International). CD34
+ cells
were then seeded in three different dilutions (10, 100 and 1000
cells per well) in culture medium supplemented with 10% patient
serum (either BC or d8 after HSCT). These cultures were
maintained with weekly two-third-medium changes, and after four
weeks cobble stone areas were analyzed by phase contrast using a
Leica DM IL HC microscope (Leica, Wetzlar, Germany).
Cytokine profiling
Analysis of serum cytokine composition was performed with
RayBio Human Cytokine Antibody Array C Series 2000
(RayBiotech, Norcross, GA, USA) according to the manufacturer’s
instructions. Serum samples were diluted 1:2 in blocking buffer.
Horseradish peroxidase fluorescence detection was done with a
LAS-3000 reader (Fujifilm Europe, Du ¨sseldorf, Germany) and
quantified using the Multi Gauge program. For normalization,
each sample data value was background-subtracted and normal-
ized by the median of positive controls represented on the array.
The profiles were further analyzed using the microarray tool
TIGR MeV v4.4 (Dana-Farber Cancer Institute, Boston, MA,
USA) and significant chemokines were identified by paired two-
sided Student’s T-test.
Statistics
All results are expressed as mean 6 standard deviation (SD) or
6 standard error of the mean (SEM). To estimate the probability
of differences we have adopted the two-sided Student’s T-test.
Probability value of P,0.05 denoted statistical significance.
Supporting Information
Figure S1 Quantitative analysis of lineage markers. The
percentage of positive cells for CD3, CD13, CD19, CD33, CD34,
CD45, CD56 and CD133 was analyzed after seven days of culture
with patient serum either BC or d8 after HSCT and either without
or with MSC co-culture (mean and SD of six patient samples and
each of them was analyzed twice; * =p,0.05; ** =p,0.01;
*** =p,0.001).
(TIF)
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PLoS ONE | www.plosone.org 8 March 2011 | Volume 6 | Issue 3 | e18012Figure S2 Heat map of all 174 human proteins repre-
sented by the Cytokines Antibody Array.
(TIF)
Figure S3 Effects of PDGF on in vitro expansion of HPC.
CD34
+ cells were stained with CFSE and cultured for seven days
in culture medium with TPO, FGF and SCF supplemented with
different concentrations of PDGF. PDGF did not affect prolifer-
ation of HPC without stromal support (A), whereas addition of
100 ng/mL PDGF slowed cell division of HPC in co-culture with
MSC (B; n=4). CFU potential was not consistently affected by
addition of PDGF (C, D; n=4; error bars represent SD).
(TIF)
Figure S4 Effects of MCP-1 on in vitro expansion of
HPC. CD34
+ cells were stained with CFSE and cultured for seven
days in culture medium either with 10% patient serum (BC; A) or
with TPO, FGF and SCF (B). Addition of different concentrations
of MCP-1 did not affect proliferation or CD34 expression of HPC.
(TIF)
Author Contributions
Conceived and designed the experiments: TW EJ OG WW. Performed the
experiments: TW GB AS CMK. Analyzed the data: TW GB EJ OG AS
CMK DMP WD THB WW. Contributed reagents/materials/analysis
tools: EJ OG DMP WD THB. Wrote the paper: TW WW.
References
1. Gratwohl A, Baldomero H, Schwendener A, Rocha V, Apperley J, et al. (2009)
The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and
novel cellular therapies. Bone Marrow Transplant 43: 275–291.
2. Thomas ED, Lochte HL, Lu WC, Ferrebee JW (1957) Intravenous infusion of
bone marrow in patients receiving radiation and chemotherapy. N Engl J Med
257: 491–496.
3. Spiegel A, Kalinkovich A, Shivtiel S, Kollet O, Lapidot T (2008) Stem cell
regulation via dynamic interactions of the nervous and immune systems with the
microenvironment. Cell Stem Cell 3: 484–492.
4. Broxmeyer HE, Douglas GW, Hangoc G, Cooper S, Bard J, et al. (1989)
Human umbilical cord blood as a potential source of transplantable
hematopoietic stem/progenitor cells. Proc Natl Acad Sci U S A 86: 3828–3832.
5. Zhang CC, Kaba M, Iizuka S, Huynh H, Lodish HF (2008) Angiopoietin-like 5
and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic
stem cells as assayed by NOD/SCID transplantation. Blood 111: 3415–3423.
6. Huang S, Law P, Young D, Ho AD (1998) Candidate hematopoietic stem cells
from fetal tissues, umbilical cord blood vs. adult bone marrow and mobilized
peripheral blood. Exp Hematol 26: 1162–1171.
7. Oostendorp RA, Audet J, Eaves CJ (2000) High-resolution tracking of cell
division suggests similar cell cycle kinetics of hematopoietic stem cells stimulated
in vitro and in vivo. Blood 95: 855–862.
8. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, et al. (2010)
Notch-mediated expansion of human cord blood progenitor cells capable of
rapid myeloid reconstitution. Nat Med 16: 232–236.
9. Walenda T, Bork S, Horn P, Wein F, Saffrich R, et al. (2010) Co-Culture with
Mesenchymal Stromal Cells Increases Proliferation and Maintenance of
Hematopoietic Progenitor Cells. J Cell Mol Med 14: 337–350.
10. Huang GP, Pan ZJ, Jia BB, Zheng Q, Xie CG, et al. (2007) Ex vivo expansion
and transplantation of hematopoietic stem/progenitor cells supported by
mesenchymal stem cells from human umbilical cord blood. Cell Transplant
16: 579–585.
11. Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD,
et al. (2010) Mesenchymal and haematopoietic stem cells form a unique bone
marrow niche. Nature 466: 829–834.
12. Boitano AE, Wang J, Romeo R, Bouchez LC, Parker AE, et al. (2010) Aryl
hydrocarbon receptor antagonists promote the expansion of human hemato-
poietic stem cells. Science 329: 1345–1348.
13. Wilson A, Laurenti E, Oser G, van der Wath RC, Blanco-Bose W, et al. (2008)
Hematopoietic Stem Cells Reversibly Switch from Dormancy to Self-Renewal
during Homeostasis and Repair. Cell 135: 1118–1129.
14. Ho AD, Wagner W (2007) The beauty of asymmetry - asymmetric divisions and
self-renewal in the hematopoietic system. Current Opinion in Hematology 14:
330–336.
15. Marciniak-Czochra A, Stiehl T, Ho AD, Jaeger W, Wagner W (2009) Modeling
of Asymmetric Cell Division in Hematopoietic Stem Cells - Regulation of Self-
Renewal is Essential for Efficient Repopulation. Stem Cells Dev 18: 377–385.
16. Blank U, Karlsson G, Karlsson S (2008) Signaling pathways governing stem-cell
fate. Blood 111: 492–503.
17. da Silva CL, Goncalves R, Crapnell KB, Cabral JM, Zanjani ED, et al. (2005) A
human stromal-based serum-free culture system supports the ex vivo expansion/
maintenance of bone marrow and cord blood hematopoietic stem/progenitor
cells. Exp Hematol 33: 828–835.
18. Goncalves R, da Silva CL, Cabral JM, Zanjani ED, Almeida-Porada G (2006) A
Stro-1(+) human universal stromal feeder layer to expand/maintain human bone
marrow hematopoietic stem/progenitor cells in a serum-free culture system. Exp
Hematol 34: 1353–1359.
19. Klaus J, Herrmann D, Breitkreutz I, Hegenbart U, Mazitschek U, et al. (2007)
Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508
patients with multiple myeloma undergoing autologous peripheral blood stem
cell transplantation. Eur J Haematol 78: 21–28.
20. Olivieri A, Offidani M, Montanari M, Ciniero L, Cantori I, et al. (1998) Factors
affecting hemopoietic recovery after high-dose therapy and autologous
peripheral blood progenitor cell transplantation: a single center experience.
Haematologica 83: 329–337.
21. Wang S, Nademanee A, Qian D, Dagis A, Park HS, et al. (2007) Peripheral
blood hematopoietic stem cell mobilization and collection efficacy is not an
independent prognostic factor for autologous stem cell transplantation.
Transfusion 47: 2207–2216.
22. Lyons AB, Parish CR (1994) Determination of lymphocyte division by flow
cytometry. J Immunol Methods 171: 131–137.
23. Gotze KS, Schiemann M, Marz S, Jacobs VR, Debus G, et al. (2007) CD133-
enriched CD34(-) (CD33/CD38/CD71)(-) cord blood cells acquire CD34 prior
to cell division and hematopoietic activity is exclusively associated with CD34
expression. Exp Hematol 35: 1408–1414.
24. Wilson A, Trumpp A (2006) Bone-marrow haematopoietic-stem-cell niches. Nat
Rev Immunol 6: 93–106.
25. Wein F, Pietsch L, Saffrich R, Wuchter P, Walenda T, et al. (2010) N-Cadherin
is expressed on Human Hematopoietic Progenitor Cells and Mediates
Interaction with Human Mesenchymal Stromal Cells. Stem Cell Research 4:
129–139.
26. Wagner W, Roderburg C, Wein F, Diehlmann A, Frankhauser M, et al. (2007)
Molecular and Secretory Profiles of Human Mesenchymal Stromal Cells and
their Abilities to Maintain Primitive Hematopoietic Progenitors. Stem Cells 10:
2638–2657.
27. Zhang J, Niu C, Ye L, Huang H, He X, et al. (2003) Identification of the
haematopoietic stem cell niche and control of the niche size. Nature 425:
836–841.
28. Andrade PZ, dos Santos F, Almeida-Porada G, da Silva CL, S Cabral JM (2010)
Systematic delineation of optimal cytokine concentrations to expand hemato-
poietic stem/progenitor cells in co-culture with mesenchymal stem cells. Mol
Biosyst 6: 1207–1215.
29. Walenda T, Bokermann G, Ventura Ferreira MS, Piroth D, Hieronymus T,
et al. (2011) Synergistic effects of growth factors and mesenchymal stromal cells
for expansion of hematopoietic stem and progenitor cells. Experimental
Hematology, in print.
30. Himburg HA, Muramoto GG, Daher P, Meadows SK, Russell JL, et al. (2010)
Pleiotrophin regulates the expansion and regeneration of hematopoietic stem
cells. Nat Med 16: 475–482.
31. Yoshimura C, Nomura S, Katsura K, Yamaguchi K, Fukuhara S (2000)
Thrombopoietin levels in patients undergoing autologous peripheral blood stem
cell transplantation. Vox Sang 78: 106–112.
32. Hsu HC, Lee YM, Tsai WH, Jiang ML, Ho CH, et al. (2002) Circulating levels
of thrombopoietic and inflammatory cytokines in patients with acute
myeloblastic leukemia and myelodysplastic syndrome. Oncology 63: 64–69.
33. Chen YM, Whang-Peng J, Liu JM, Kuo BI, Wang SY, et al. (1996) Serum
cytokine levelfluctuations inchemotherapy-inducedmyelosuppression. JpnJClin
Oncol 26: 18–23.
34. Stier S, Ko Y, Forkert R, Lutz C, Neuhaus T, et al. (2005) Osteopontin is a
hematopoietic stem cell niche component that negatively regulates stem cell pool
size. J Exp Med 201: 1781–1791.
35. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, et al. (2010)
Development of monocytes, macrophages, and dendritic cells. Science 327:
656–661.
36. Sarris AH, Broxmeyer HE, Wirthmueller U, Karasavvas N, Cooper S, et al.
(1993) Human interferon-inducible protein 10: expression and purification of
recombinant protein demonstrate inhibition of early human hematopoietic
progenitors. J Exp Med 178: 1127–1132.
37. Su RJ, Zhang XB, Li K, Yang M, Li CK, et al. (2002) Platelet-derived growth
factor promotes ex vivo expansion of CD34+ cells from human cord blood and
enhances long-term culture-initiating cells, non-obese diabetic/severe combined
immunodeficient repopulating cells and formation of adherent cells.
Br J Haematol 117: 735–746.
38. Noroozi AA, Kheirandish M, Abolghasemi H, Gharehbaghian A (2010) Platelet
growth factors suppress ex vivo expansion and enhance differentiation of
umbilical cord blood CD133(+) stem cells to megakaryocyte progenitor cells.
Growth Factors Epub ahead of print.
39. Weissinger EM, Zurbig P, Ganser A (2009) Proteomics studies after
hematopoietic stem cell transplantation. Methods Mol Biol 506: 437–452.
Serum Stimulates Hematopoietic Progenitor Cells
PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e1801240. Sauvageau G, Humphries RK (2010) Medicine. The blood stem cell Holy Grail?
Science 329: 1291–1292.
41. Kurita M, Aiba-Kojima E, Shigeura T, Matsumoto D, Suga H, et al. (2008)
Differential effects of three preparations of human serum on expansion of
various types of human cells. Plast Reconstr Surg 122: 438–448.
42. Horn P, Bokermann G, Cholewa D, Bork S, Walenda T, et al. (2010)
Comparison of Individual Platelet Lysates for Isolation of Human Mesenchymal
Stromal Cells. Cytotherapy 12: 888–898.
43. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays. J Immunol Methods 65:
55–63.
44. Ploemacher RE, van der Sluijs JP, Voerman JS, Brons NH (1989) An in vitro
limiting-dilution assay of long-term repopulating hematopoietic stem cells in the
mouse. Blood 74: 2755–2763.
Serum Stimulates Hematopoietic Progenitor Cells
PLoS ONE | www.plosone.org 10 March 2011 | Volume 6 | Issue 3 | e18012